Sernova to Present at H.C. Wainwright Annual Global Investment Conference and LifeSci Partners HealthTech Symposium
Sernova Corp. (OTCQB: SEOVF) will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022, and the LifeSci Partners HealthTech Symposium on September 20-21, 2022. CEO Dr. Philip Toleikis will present at both events, with the Wainwright presentation scheduled for September 13 at 9:00 AM ET. The company aims to highlight its regenerative medicine technologies, including the Cell Pouch System for chronic diseases like diabetes. For more details, visit Sernova's investor events page.
- None.
- None.
LONDON, Ontario, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced it will be presenting at the upcoming H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022, as well as the LifeSci Partners HealthTech Symposium being held September 20-21, 2022. Company management will also be engaging in 1x1 meetings at the H.C. Wainwright conference.
| H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022 | |
| Date: | Tuesday, September 13, 2022 |
| Time: | 9:00 – 9:30 AM ET |
| Location: | Lotte New York Palace |
| Presenter: | Dr. Philip Toleikis, President & CEO, Sernova Corp |
| Webcast: | https://journey.ct.events/view/0510fdaf-5167-4406-a0fe-d487089da046 |
| Conference Website | https://hcwevents.com/annualconference/ |
*a replay of the presentation will be available for 90 days
| LifeSci Partners HealthTech Symposium – September 20-21, 2022 | |
| Date: | Wednesday, September 21, 2022 |
| Time: | 8:00 – 8:25 AM ET |
| Presenter: | Dr. Philip Toleikis, President & CEO, Sernova Corp |
| Format: | Virtual |
| Webcast: | https://wsw.com/webcast/lifesci6/register.aspx?conf=lifesci6&page=sva&url=https://wsw.com/webcast/lifesci6/sva/1973682 |
| Conference Website | https://www.meetmax.com/sched/event_87317/conference_home.html |
*a replay of the presentation will be available for 90 days
Details of the events can also be found on the events page of the Sernova website at https://www.sernova.com/investor/?disclaimer=1#Events. If interested in arranging a 1x1 meeting request at the H.C. Wainwright conference, please contact the conference organizers.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic technologies for chronic diseases, including diabetes, thyroid disease, and blood disorders including hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for diabetes with its regenerative cell therapy platform technologies, including its proprietary Cell Pouch™. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or factors missing from the body to treat chronic diseases. Sernova’s Cell Pouch System has already shown it can potentially provide a ‘functional cure’ to people with type 1 diabetes in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing its proprietary conformal coating technology in collaboration with the University of Miami to cloak the therapeutic cells from the immune system attack with the goal to eliminate the need for chronic immunosuppressives. In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. This collaboration potentially provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the clinic in two additional programs that utilize its Cell Pouch System – an implantable cell therapy for benign thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
| Corporate: | Investors: | Media: |
| Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 www.sernova.com | Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577 | Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.com Tel: 646-791-9705 |
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What will Sernova Corp. present at the H.C. Wainwright conference?
When is Sernova scheduled to present at the H.C. Wainwright conference?
What is the date of the LifeSci Partners HealthTech Symposium where Sernova will present?
Who is the presenter for Sernova's upcoming conferences?
How can I access Sernova's presentation replays?
